Innate pharma presents encouraging data on IPH 1101 at the American society of clinical oncology's 2006 annual meeting and moves its drug candidate into phase II kidney cancer clinical trial.
| PR in english | 122.53 KB |
| CP en français | 98.57 KB |
Innate pharma presents encouraging data on IPH 1101 at the American society of clinical oncology's 2006 annual meeting and moves its drug candidate into phase II kidney cancer clinical trial.
| PR in english | 122.53 KB |
| CP en français | 98.57 KB |